Ovarian Cancer

Maintenance treatment with Lynparza plus Avastin over Avastin alone provided a certain group of patients with ovarian cancer a substantial survival benefit.

Progression-free survival improved with Zejula compared with placebo in patients with BRCA-mutated ovarian cancer with no new safety signals.

Each month, we take a look back at the most popular CURE® stories. Here are the top five stories for May 2021.

Evidence from a phase 3 trial does not support the addition of Tecentriq to a specific chemotherapy regimen with Avastin for patients with newly diagnosed stage 3 or 4 ovarian cancer.

This maintenance therapy approach approved progression-free survival without a major impact on quality of life in patients with newly diagnosed ovarian cancer with a BRCA mutation who recently responded to chemotherapy.

Vulnerable older patients with advanced ovarian cancer do not respond well to carboplatin treatment alone compared to a combination with paclitaxel.

Today is World Ovarian Cancer Day, and in honor of this day that was created in 2013 to raise awareness about the disease, CURE® is rounding up the latest news and updates in this cancer space.

“We’re all blessed that there are so many dedicated, caring health care professionals willing to step in and fill the void when members of the team move or retire,” writes a patient with cancer. “We can never forget how tough a gig it is or say thank you enough.”

Clinical trials are often the key to advancements in treating ovarian cancer. As part of its “Speaking Out” video series, CURE® spoke with Dr. Debra Richardson about what patients should know about joining a trial.

On social media, CURE® recently asked its readers to share if they sought a second opinion when discussing their cancer diagnosis and treatment. Here’s what some of them said.

Despite on-treatment clinical progression, patients treated with Avastin and standard chemotherapy had a median progression-free survival of 11.8 months compared with 8.8 months in those treated with standard chemotherapy alone.

Patients with platinum-sensitive relapsed ovarian cancer who underwent surgery then chemotherapy had a progression-free survival of 17.4 months compared with 11.9 months in those who underwent chemotherapy alone.

Polymerase (PARP) inhibitors continue to improve progression-free survival over placebo in women with recurrent, platinum-sensitive ovarian cancer.

The phase 3 ARIEL4 trial evaluated Rubraca (rucaparib) versus chemotherapy in patients with ovarian cancer and a BRCA mutation who did not respond to two or more lines of chemotherapy.

Fertility treatments led to a cancer diagnosis but also opened the door to adoption and a new view on life.

Being creative has helped this ovarian cancer survivor during her journey. She recommends that people use their energy in a positive way and do something that will make a difference in their lives.

From a Louisiana-based motorcycle club holding a 57-mile ride to raise money for a fellow member with ovarian cancer to the World Health Organization (WHO) announcing an initiative to reduce global breast cancer mortality by 2.5 million by 2040, here’s what’s happening in the cancer space this week.

An ovarian cancer survivor shares that although she’s been frustrated and mad about a recent recurrence in her lymph nodes, she still celebrates the life that she’s been blessed with.

Although a gynecologic oncologist has spent a good part of her career helping patients during their cancer journeys, she took it upon herself to take one step further to educate women on how they can advocate for themselves and potentially prevent cancer before it impacts their lives.

A roundup of some of the latest news and updates for patients with ovarian cancer from CURE®.

Two evaluations for treatment responses in women with ovarian, fallopian tube or primary peritoneal carcinoma may need to take into consideration other factors such as other existing conditions.

A cancer survivor remembers his wife who died of complications from ovarian cancer on Valentine’s Day several years ago. His advice to everyone: Holidays gradually become positive reflections of all that was good before cancer took it away.

At the moment it may be hard to realize, but your life is not over because of cancer.

Women who reported using oral contraceptives had a decreased risk of endometrial and ovarian cancer, compared to those who never used the hormone medications. The data also indicated the association extended up to three decades after patients stopped using the contraceptives.

It’s okay for me to not feel like celebrating my 5-year cancerversary in a world that is upside down and backward because of COVID-19. Yes, I’m grateful and blessed, but I’m not bullet-proof. I’m human. I don’t have to feel guilty. None of us do.

In an interview with CURE®, the “Felicity” and “Scandal” actor spoke about his experience as a caregiver to his mother, and why women should not just watch and wait for their ovarian cancer to recur.

A gynecologic oncology expert from the University of California, Davis reviewed early-stage ovarian cancer and the importance of knowing what options are available before, during and after treatment.

A roundup of some ovarian cancer news and updates that occurred in 2020 that patients may have missed.

Women with ovarian cancer report a better quality of life when treated with a combination of Keytruda, Avastin and oral metronomic cyclophosphamide.

Keytruda (pembrolizumab), Avastin (bevacizumab) and cyclophosphamide contributed to a clinical benefit in 95% of women in the trial and a durable treatment response of 12 months or longer in 25% of women.